6533b7defe1ef96bd127695d

RESEARCH PRODUCT

Effects of Recombinant Human Erythropoietin (rHuEPO) on Tumor Control in Patients with Cancer-Induced Anemia

Peter VaupelJoachim FandreyWolfgang JelkmannJürgen DunstMathias FreundP. FeyerAndreas Engert

subject

OncologyCancer Researchmedicine.medical_specialtyAnemiamedicine.medical_treatmentAntineoplastic AgentsComorbiditylaw.inventionHemoglobinslawNeoplasmsInternal medicinemedicineHumansPractice Patterns Physicians'ErythropoietinClinical Trials as TopicChemotherapyTumor hypoxiabusiness.industryCancerAnemiaHealth Care CostsHematologyTumor Oxygenationmedicine.diseaseRecombinant ProteinsEndocrinologyOncologyErythropoietinPractice Guidelines as TopicRecombinant DNAHemoglobinbusinessmedicine.drug

description

It is well recognized that anemia-induced tumor hypoxia is associated with a reduced sensitivity of tumors to radiation and some forms of chemotherapy. Thus, the correction of lower hemoglobin (Hb) concentrations with recombinant human erythropoietin (rHuEPO) can play an essential role by improving tumor oxygenation. Based on evidence from a number of trials, treatment with rHuEPO will effectively ameliorate anemia and improve quality of life. However, one of the most essential prerequisites for achieving this benefit is the use of rHuEPO in agreement with the evidence-based ASCO/ASH-guidelines recommending a target Hb concentration of 12 g/dl (7.44 mmol/l).

yearjournalcountryeditionlanguage
2005-04-21Oncology Research and Treatment
https://doi.org/10.1159/000084033